Results 191 to 200 of about 150,265 (357)

A review of adult and pediatric post-transplant liver pathology. [PDF]

, 1987
Demetris, AJ, Jaffe, R, Starzl, TE
core  

Fast Quantitative Evaluation of the Amelioration Effect in MASLD During Semaglutide Treatment Using Ultrasound‐Derived Fat Fraction and Fat‐to‐Muscle Ratio

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a chronic liver disease. Research into a feasible, rapid, and effective assessment method is crucial for evaluating the therapeutic effects of semaglutide in MASLD. This prospective study utilized ultrasound‐derived fat fraction measurement and fat‐to‐muscle ratio to evaluate hepatic ...
Yunlin Huang, Ruping Yang, Ying Wang, Xiu‐Yun Lu, Li Wei, Rui Cheng, Juan Cheng, Yijie Qiu, Shiwen Wang, Bo Li, Yi Dong   +10 more
wiley   +1 more source

Protein Priming Followed by a Replication-Competent VSV-GP Vector Boost Induces Sustained Immune Control in Therapeutic Hepatitis B Vaccination. [PDF]

Vaccines (Basel)
Su J, Kosinska AD, Miko S, Ates Öz E, Laer DV, Kimpel J, Protzer U.   +6 more
europepmc   +1 more source

SEROPREVALENCE OF HEPATITIS B SURFACE ANTIGEN AMONG PREGNANT WOMEN ATTENDING ANTENATAL CLINIC IN GOVT . GENERAL HOSPITAL, ANANTAPURAMU (A. P.)

, 2015
Shanti Reddy B, P. Venkateswarlu, S. Umadevi, Naga Jyothi B, M. Sailaja   +4 more
openalex   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Trends in clinical intervention practice for preventing mother-to-child transmission of hepatitis B virus in Guangdong Province, 2021-2023. [PDF]

Hum Vaccin Immunother
Gao S, Xie T, Cai M, Su M, Zhao T, Zhang X, Zhang S, Wang M, Xu Q, Cheng Y, Cui F, Liu F.   +11 more
europepmc   +1 more source

Forefront of the viral chronic hepatitis treatment. Treatment of the case for which the treatment plans can not be decided.Chronic hepatitis B. 1. Treatment of the e antigen positive case of high virus quantity.

, 2004
Kazuaki Chayama
openalex   +2 more sources

Antiviral Resistance Mutations Potentiate hepatitis B virus Immune Evasion through Disruption of its Surface Antigen a Determinant [PDF]

, 2008
Richard D. Sloan, Samreen Ijaz, Penny L. Moore, Tim J. Harrison, Chong‐Gee Teo, Richard S. Tedder   +5 more
openalex   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Virus Biomimetic-Delivery Systems for the Production of Vaccines. [PDF]

Biomimetics (Basel)
Barbinta-Patrascu ME, Negut I, Bita B.
europepmc   +1 more source